

Index

A

- ACF/SNF2, 208
 - ACTL6A*, 96–97
 - ACTL6B*, 88
 - Acute lymphoblastic leukemia (ALL)
 - DNMT3A mutations, 116–117
 - NSD2 mutations, 27
 - SETD2 mutation, 173
 - UTX mutations, 75–76
 - Acute myeloid leukemia (AML)
 - ASXL protein mutations, 159–160
 - BRD4 pathway, 295
 - cohesin mutations, 226–227
 - DNA hypomethylating drug management, 274, 279
 - DNMT3A mutations
 - age-related clonal hematopoiesis and preleukemic clones, 117–118
 - minimal residual disease and relapse, 115–116
 - overview, 112–114
 - prognosis, 114–115
 - MLL3 suppression, 73
 - NuP98-NSD1, 25
 - SETD2 mutation, 173
 - TET2 mutations, 126, 130
 - ACVR1*, 56
 - ACY-1215. *See* Ricolinostat
 - Additional sex combs-like (ASXL) proteins
 - ASXL1 and TET2 mutations, 126
 - BAP1 interactions, 155–159
 - developmental disorder mutations, 160–161
 - discovery
 - Drosophila*, 154
 - mammals, 154–155
 - genes, 153
 - histone H2A deubiquitination role, 164
 - mutations in cancer
 - functional effects, 163–164
 - overview, 159–160
 - phenotypic analysis of function, 161–163
 - PRC2 function, 164–165
 - AEBP2*, 10
 - AF10, 45
 - AF9, 45–46
 - ALK2, 56
 - ALL. *See* Acute lymphoblastic leukemia
 - ALT pathway, ATRX/DAXX loss in cancer, 195–196, 333, 339
 - AML. *See* Acute myeloid leukemia
 - AML-ETO*, 130
 - Angiogenesis, histone deacetylases in cancer, 250–251
 - APC/C, 220
 - Apoptosis, histone deacetylases in cancer, 247–248
 - ARID1A/B, 88, 92–94, 98
 - ARID2, 88, 94–95
 - Arp7, 96
 - Arp9, 96
 - ARV-825, 289
 - ASH2, 44
 - ASXL proteins. *See* Additional sex combs-like proteins
 - ATB, 368
 - ATM, 248
 - ATR, 248
 - ATRX, 57, 62
 - ALT pathway in cancer, 195–196, 333, 339
 - EZH2 interactions, 193
 - functional overview, 185, 187, 191
 - G4 DNA association, 192
 - heterochromatin association, 190, 193
 - histone variant deposition regulation, 189–190
 - macroH2A regulation, 337
 - mouse models of deficiency, 187–189
 - mutation in cancer, 186, 188, 193–195
 - prospects for study, 196
 - retrotransposon association, 192
 - telomeric repeat association, 190, 192
 - ZNF gene association, 192–193
 - ATRX syndrome, 187–188, 195, 333
 - Autophagy, histone deacetylases in cancer, 251–252
 - Azacitidine, 273, 275
- ## B
- BAF. *See also* Polybromo-associated BAF
 - BAF53A, 96–97
 - cancer mutations, 88–91
 - DNA repair and chromosome stability role, 97
 - functional overview of complex, 87–88
 - homology between species, 85
 - nucleosome remodeling, 332–333
 - therapeutic targeting, 98
 - topoisomerase synergy, 97–98
 - BAP. *See* Brahma-associated protein
 - BAP1
 - ASXL protein interactions, 155–159
 - PRC2 function, 164–165
 - BCAR4, 368

Index

- B-cell lymphoma
 EZH2 hyperactivating mutants, 7–8, 10, 13
 MLL4 mutation, 73
- Bcl-2, 248
- BCL2*, 291, 294, 296
- Beclin 1, 252
- Belinostat, 254
- β -Catenin, 147, 206
- BET proteins. *See also* BRD4
 domain structure, 286–287
 functional overview, 285–288
 inhibitors
 BRD4–NUT fusion protein targeting in NUT
 midline carcinoma, 289–291
 cancer cell sensitivity, 291–292, 294–296
 mechanism of action, 294–296
 phase I clinical trials, 292–294
 resistance, 296–297
 small-molecule inhibitors, 288–289
- BI-2536, 288
- BIX-01294, 348
- Bladder cancer
 cohesin mutations, 227–229
 NSD3 amplification, 29
 SETD2 mutation, 173
 UTX mutations, 75
- BMF, 248
- Bohring–Opitz syndrome (BOS), 160–161
- BOS. *See* Bohring–Opitz syndrome
- 53BP1, 248
- BRAF, 209–210, 272
- Brahma-associated protein (BAP)
 Drosophila function, 86–87
 homology between species, 85
 PBAP complex, 87
- BRCA, 208, 248
- BRCA1, 141, 156
- BRD4470, 348
- BRD4–NUT fusion protein, targeting in NUT midline
 carcinoma, 289–291
 BRD4
 functions, 288
 inhibitors. *See* BET proteins
 mixed-lineage leukemia studies, 47
 NSD interactions, 30, 32
 structure, 286–287
- Breast cancer
 NSD3 amplification, 29
 p300 mutations, 140
- BRG, cancer mutations, 90, 92
- BRM, cancer mutations, 92
- C**
- CAMKMT, 351
- CBB1003, 311
- CBB1007, 311
- CBP. *See* CREB-binding protein
- CCAT-1, 365
- CDA. *See* Cytosine deaminase
- CDH1, 249–250
- CDK6, 291
- CDK8, 47
- CDKN2A, 229
- CDKN2A, PRC2 deregulation and cancer, 12–13
- CdLS. *See* Cornelia de Lange syndrome
- CENP-A, 54, 337
- CHD proteins. *See* Chromatin helicase DNA-binding
 proteins
- Chk1, 189
- Chromatin helicase DNA-binding (CHD) proteins
 CHD1, 203–204, 332
 CHD2, 204–205
 CHD3, 205
 CHD4, 205–206, 208
 CHD5, 205–208
 CHD6, 208, 210
 CHD7, 208–210
 CHD8, 30, 208–209
 CHD9, 208, 210
 classification, 202–203
 functional overview, 201
 structure, 202
- Chronic lymphocytic leukemia (CLL)
 CHD2 mutations, 205
 NSD2 mutations, 27
- Chronic myelomonocytic leukemia (CMML)
 ASXL1 mutations, 159
 DNA hypomethylating drug management, 275
- CIMP1, 209
- CKDN1A, 366
- CLL. *See* Chronic lymphocytic leukemia
- CMML. *See* Chronic myelomonocytic leukemia
- Cohesin
 DNA interactions, 219
 establishment and dissolution, 220–221
 functional overview, 217, 221, 223–224
 knockout mouse models, 222–223
 mutation in cancer
 acute myeloid leukemia, 226–227
 bladder cancer, 227–229
 Ewing sarcoma, 229
 hematopoietic cell knockdown models,
 226–227
 identification, 224–226
 nomenclature, 218
 prospects for study, 230
 structure, 218–219
 subcellular localization, 220
- Colorectal cancer
 NSD3 amplification, 29
 p300 mutations, 140

- COMPASS histone lysine methyltransferases.
 See MLL3; MLL4
- Cornelia de Lange syndrome (CdLS), 217
- CPI-0610, 292
- CREB-binding protein (CBP)
 cancer promotion studies, 141–142
 cell cycle regulation
 nontranscriptional effects, 139
 overview, 138–139
 transcriptional coactivation, 139
 chromatin modulation in cancer, 145–146
 epigenome linking to cellular energetics, 147
 functional overview, 137–138
 histone acetylation balance and cancer, 146–147
 levels in cancer, 144–145
 mutation analysis, 142–144
 prospects for study, 147–148
 therapeutic targeting, 147
 tumor-suppressor activity, 140–141
- CREST, 88
- CtBP, 249
- CTCF, 217–219, 226, 228, 230, 291
- CTLA4, 260, 277
- CTNNB1, 363
- CUDC-101, 257
- CUDC-907, 257
- Cytosine deaminase (CDA), 276
- D**
- DAXX, 57
 ALT pathway in cancer, 195–196, 333, 339
 functional overview, 185, 187, 189
 histone variant deposition regulation, 189–190
 mutation in cancer, 193–195
 prospects for study, 196
 telomeric repeat association, 190, 192
- DCK. *See* Deoxycytidine kinase
- Decitabine, 273, 275
- Deoxycytidine kinase (DCK), 276
- Diffuse intrinsic pontine glioma (DIPG), 55–57, 60
- Dinaciclib, 289
- DIPG. *See* Diffuse intrinsic pontine glioma
- DNA methyltransferase (DNMT)
 CGI methylator phenotype in cancer, 272
 DNMT3A
 acute lymphoblastic leukemia mutations,
 116–117
 acute myeloid leukemia mutations
 age-related clonal hematopoiesis and
 preleukemic clones, 117–118
 minimal residual disease and relapse,
 115–116
 overview, 112–114
 prognosis, 114–115
 DNA methylation studies, 110–111
 gene structure, 109
 hematopoiesis role, 111–112
 mutation in cancer, 112–113
 myelodysplastic syndrome mutations, 116
 myelodysplastic/myeloproliferative neoplasm
 mutations, 116
 peripheral T-cell lymphoma mutation, 117
 structure, 108, 110
 therapeutic prospects, 118, 119
 inhibitors
 combination therapy, 277–278
 development, 278–280
 experimental studies, 276–277
 immune response studies, 277
 overview, 272–275
 resistance, 275–276
 tumor microenvironment effects, 279–280
 mammalian genes and functions, 107–108
 overview, 271–272
- DNA repair
 BAF role, 97
 histone deacetylases in cancer, 248–249
- DNMT. *See* DNA methyltransferase
- DOT1L, 45–46, 118, 350–351
- Down syndrome, 225
- DPF1, 88
- E**
- E1A, 138
- E2F, 139
- E2F1, 209, 320
- EED, 2, 4–5, 10–11
- ENL, 45
- ERCC1, 258
- ERG, 204
- Esco, 220, 224
- Ewing sarcoma, cohesin mutations, 229
- EZH2, 2, 4–8, 10–14, 26–28, 59, 193,
 207, 278, 334
- F**
- FAS, 247
- FGFR1, 56
- FGFR3, 26
- FK228. *See* Romidepsin
- FLIP, 247–248
- FLT3, 25
- FLT3, 130
- Follicular lymphoma
 EZH2 hyperactivating mutants, 8, 13
 MLL4 mutation, 73
- FOXG1, 56–57
- FOXO1, 204
- FUS, 248

Index

G

G9a, 347–349
GATA1, 225
Glioma, TET2 mutations, 131
GLP, 347–349
GSK-J4, 319–320
GSKJ14, 60

H

H3F3A, 57, 194
H3F3B, 57
HCl-2509, 313
HDACs. *See* Histone deacetylases
HER2, 257
HIF-1 α , 250
Histone deacetylases (HDACs)
cancer
combination therapy, 277–278
defects, 238–247, 334
inhibitor therapy
class I inhibitors, 254–256
class IIa inhibitors, 255–257
class IIb inhibitors, 255, 257
clinical landscape, 258–260
multipharmacological inhibitors, 257–258
nonselective inhibitors, 254
overview, 252–253
mechanisms of cancer development
angiogenesis, 250–251
apoptosis, 247–248
autophagy, 251–252
cell cycle, 247
DNA repair, 248–249
metastasis, 249–250
overview, 237–239
Histone H2A, deubiquitination role of
ASXL proteins, 164
Histone H3G34R/V, 62
Histone H3K27
epigenetics overview, 54–55
methyltransferases and demethylases, 53–54
mutations
cancer, 55–57
oncogenesis mechanisms, 57–61
Histone H3K36, oncogenesis mechanisms, 61–62
Histone lysine demethylases
cancer aberrations, 305–306
catalytic mechanism, 304–305
JmjC family
inhibitors
bifunctional, 315–316, 318
miscellaneous inhibitors, 319–320
2-OG-dependent enzymes, 314–315
structures, 315–316
table, 317–318

KDM4, 312–314, 319–320
LSD1
inhibitors
bifunctional, 312–313
cytotoxic effects, 308–309
irreversible, 306–308
non-monoamine oxidase inhibitors, 313
reversible, 311–312
structures, 307–308
overview, 306
nonhistone lysine demethylases. *See* Lysine demethylases
overview of histone lysine methylation, 303
prospects for study, 320–321
Histone lysine methyltransferases. *See also* Histone H3K27; Nuclear receptor–binding SET domain histone lysine methyltransferases; Polycomb repressive complex 2; SETD2
acetylation balance and cancer, 146–147
functional overview, 21
nonhistone lysine methyltransferases. *See* Lysine methyltransferases
Histone variants. *See*, Nucleosome
HMR, 86
HOTAIR, 367
HP1, 335, 348
hPAF, 203
2-Hydroxyglutarate, TET2 regulation, 128–129

I

iBET, 288, 292
IDAX, 129
IDH1, 128–129, 194, 272
IDH2, 128–129, 272
Ino80, 332
IOX1, 319
ITD, 130

J

JAK2, 126
JARID2, 10
JIB-04, 320
JMJD2A, 206
JQ1, 288–289, 291, 294–296
JUNB, 363

K

KAP-1, 208
KDM2, 54
KDM2B, 3
KDM4, 54, 312–314, 319–320
KDM6, 53
KLF-4, 250

KMT2A. *See* *MLL1/KMT2A* fusion
KRAS, 203, 209–210

L

LEDGF, 44, 176
LET, 368
LGG. *See* Lower grade glioma
Liver cancer, NSD3 amplification, 29
LMK235, 256
lncRNA. *See* Long noncoding RNA
Long noncoding RNA (lncRNA)
 cell growth and tumor-suppression regulation,
 364–366
 cell survival enhancement, 366–367
 chromatin
 interactions, 362
 regulation, 362–363
 functions
 nuclear organization, 360–362
 transcriptional regulation, 363–364
 overview, 359–360
 p53 pathway, 366
 prospects for study, 368–369
 tumor invasion and metastasis studies, 367–368
Lower grade glioma (LGG), ATRX mutations, 194
LSD1, 278, 304–313, 318, 351
LSD2, 305
LUNAR1, 364
Lung cancer, NSD3 amplification, 29
Lysine demethylases
 cancer pathway visualization, 352–353
 JmjC enzymes, 351–352
 LSD1 and nonhistone substrates, 351
 overview, 343–345
Lysine methyltransferases
 cancer pathway visualization, 352–353
 overview, 343–345
SET domain proteins
 cancer mechanisms, 346
 G9a, 347–349
 GLP, 347–349
 orphan proteins associated with cancer,
 349–351
 overview, 345–346
 SETD proteins, 348–349
 SMYD2, 348–349
 SMYD3, 346–347
7 β -strand enzymes, 350–352

M

MALAT1, 362, 367
Malignant rhabdoid tumor (MRT), 95
Mantle cell lymphoma (MCL), NSD2 mutations, 27
MAOIs. *See* Monoamine oxidase inhibitors

MAP3K2, 347
MAP3K7, 203
Mau2, 219
MBD2, 278
MCI1568, 256
MCI1575, 256
MCL. *See* Mantle cell lymphoma
MDM2, 249
MDS/MPN. *See* Myelodysplastic syndrome/
 myeloproliferative neoplasm
MeCP2, 278
MEG3, 366
Melanoma
 SETD2 mutation, 173
 TET2 mutations, 131
MEN, 46
MEN1, 44, 47
Metastasis, histone deacetylases in cancer, 249–250
MI-503, 46–47
Mixed-lineage leukemia (MLL). *See also* *MLL1/KMT2A*
 fusion; MLL3; MLL4
 SETD2 mutation, 173
MLH1, 278
MLL. *See* Mixed-lineage leukemia
MLL1/KMT2A fusion
 identification in mixed-lineage leukemia, 39–41
 leukemia research tools, 40, 42
 mechanism of action, 44–46
 structure, 42–43
 super complexes, 42, 44
 therapeutic targeting, 46–48
MLL3
 COMPASS family features, 68–70
 enhancer monomethylase function, 69–71
 mutation in cancer, 71, 74
 tumor-suppressor function, 71–74
 UTX subunit function and mutation, 74–77
MLL4
 COMPASS family features, 68–70
 enhancer monomethylase function, 69–71
 mutation in cancer, 71, 74
 tumor-suppressor function, 71–74
 UTX subunit function and mutation, 74–77
Monoamine oxidase inhibitors (MAOIs), histone lysine
 demethylase inhibition, 306–307, 312
MORE, 141–142
MOZ, 141–142
MPP8, 250
MRE11, 195
MRN complex, 195
MRT. *See* Malignant rhabdoid tumor
MS-436, 288
MSH2, 249
Msx1, 29
Multiple myeloma, NSD2 overexpression, 27

Index

- MYC, 291, 294, 296
MYC, 365–367
MYCN, 62
Myelodysplastic syndrome (MDS)
 ASXL1 mutations, 160
 DNA hypomethylating drug management, 273–275,
 277, 279
 DNMT3A mutations, 116
Myelodysplastic syndrome/myeloproliferative
 neoplasm (MDS/MPN), 10, 30, 72–73
 DNMT3A mutations, 116
 TET2 mutations, 126
- N**
- NBAT-1, 367
NBS1, 195
NCL-1, 312
NEAT1, 361–362
NEAT2, 362
NFI, 56
NIPBL, 219, 225, 227
Nivolumab, 277
NKILA, 368
NKX3.1, 204
NOTCH1, 296
NPM1, 225
NSDs. *See* Nuclear receptor–binding SET domain
 histone lysine methyltransferases
Nuclear receptor–binding SET domain histone lysine
 methyltransferases (NSDs)
 conserved structural domains, 22–23
 NSD1
 cancer role, 24–25
 structure and function, 23–24
 NSD2
 cancer role, 26–27
 functional overview, 25–26
 point mutation in lymphoid malignancies, 27–28
 NSD3
 cancer role, 29–30
 functional overview, 28–29
 prospects for study, 30–32
Nucleosome
 concerted action of regulators, 338
 histone variants, 335–337
 modifications, 333–335
 remodeling, 330–333
NuP98-NSD1, 25
NURD, 208
NUT, 30
NUT midline carcinoma. *See* BRD4–NUT fusion protein
- O**
- Oct4, 204
OG-L002, 310
- OLIG2, 57
Olinone, 288
ORY-1001, 313
Ovarian cancer
 ARID1A mutation, 94
 NSD3 amplification, 29
N-Oxalylglycine (NOG), 314, 316
OXT015, 292
- P**
- p53, 141, 145, 209–210, 366
p300
 cancer promotion studies, 141–142
 cell cycle regulation
 nontranscriptional effects, 139
 overview, 138–139
 transcriptional coactivation, 139
 chromatin modulation in cancer, 145–146
 epigenome linking to cellular energetics, 147
 functional overview, 137–138
 histone acetylation balance and cancer, 146–147
 levels in cancer, 144–145
 mutation analysis, 142–144
 prospects for study, 147–148
 therapeutic targeting, 147
 tumor-suppressor activity, 140–141
PAF1, 44
Pancreatic cancer
 NSD3 amplification, 29
 UTX mutations, 75
PANDA, 366
Panobinostat, 254
PBAF. *See* Polybromo-associated BAF
PBAP. *See* Brahma-associated protein
PBRM1, renal carcinoma defects, 94–95
PcG proteins. *See* Polycomb group (PcG) proteins
PCGEM1, 362, 365
PCI-34051, 256
PCNA, 349
PD-1, 277
PD2, 203
PDLIM4, 278
Pds5, 220
PDS5B, 224
Peripheral T-cell lymphoma, DNMT3A mutation, 117
PHD2, 314
PKM2, 147
POLE, 94
Polybromo-associated BAF (PBAF)
 cancer mutations, 88–91
 DNA repair and chromosome stability role, 97
 functional overview of complex, 88
 homology between species, 85
 nucleosome remodeling role, 332
 therapeutic targeting, 98

- Polycomb group (PcG) proteins
functional overview, 2, 339
repressive complexes, 2
- Polycomb repressive complex 2 (PRC2)
ASXL proteins and BAP1 in function,
164–165
cancer expression, 5–6
composition, 2
EZH2 hyperactivating mutants, 6–8, 10
H3K27 methylation
overview, 4–5
significance in cancer, 11–12
histone H3K27 interactions, 53, 58
loss-of-function mutations in cancer, 9–11
prospects for study, 14
recruitment to chromatin, 2–4
stem cell and development functions, 5
therapeutic targeting, 13–14
transcriptional regulation, 5
tumorigenesis and deregulation, 12–13
- POT-1, 367
- PPAR γ , 204
- PRC2. *See* Polycomb repressive complex 2
- PRDM1, 350
- PRDM2, 350
- PRDM9, 350
- Prostate cancer, TET2 mutations, 131
- PRUNE2, 364
- PTEN, 364
- PVT1, 365–366
- R**
- RAD16, 331
- RAD21, 224, 226, 228–229
- RAD26, 331
- RAD50, 195
- RAD54, 331, 333
- RbBP5, 44
- Renal carcinoma
PBRM1 defects, 94–95
SETD2 mutation, 173, 178
- RGFP966, 254
- Ricolinostat (*ACY-1215*), 257
- RING1A, 2
- RING1B, 2
- RN-1, 310–311
- RNA polymerase II, 138, 170–173, 203, 285,
332, 335
- Romidepsin (*FK228*), 254, 257
- RSC complex
homology between species, 85
yeast function, 86, 332
- RUNX1, 225, 227
- RVX-208, 288–289
- RVX-297, 288
- S**
- SAFA, 366
- SAHA. *See* Vorinostat
- SET domain proteins. *See* Lysine methyltransferases;
Nuclear receptor–binding SET domain
histone lysine methyltransferases
- SETD2, 57
cancer
mutations, 170
therapeutic targeting, 178–179
chromatin structure modulation, 176
DNA damage repair, 176–177
DNA methylation and expression, 177–178
structure and function, 169–170
transcription and splice variants, 173–176
- SETD proteins, 57, 348–349
- SIRT1, 46, 249–250, 252
- SIRT3, 252
- SIRT5, 252
- SIRT6, 249
- Slit2, 250
- SMARCB1*, 95
- SMYD2, 348–349
- SMYD3, 346–347
- SNAL, 311
- SNF2H, 249
- Squamous cell carcinoma, p300/CBP mutations,
142, 144
- SS18–SSX fusion, 96
- STAG2*, 224, 226–230
- STAU-1, 363, 367
- SUZ12, 2, 5, 10–11
- SWI/SNF complex
homology between species, 85, 331
mammalian complex. *See* BAF
SWI2/SNF2, 330
yeast function, 84, 86
- Swr1, 332
- Synovial sarcoma, 95–96
- T**
- TAM. *See* Transient abnormal myelopoiesis
- T-cell lymphoma, TET2 mutations, 130–131
- TCP. *See* Tranylcypromine
- Telomere
ALT pathway in cancer, 195–196, 333
ATR χ /DAXX association, 190, 192
- TEN-010, 292
- TERC, 367
- TERRA, 367
- TET2
DNA hypomethylating drug management in
mutations, 275
glioma mutations, 131

Index

TET2 (*Continued*)

- hematological disease mutations, 126
- leukemogenesis mechanisms, 130
- melanoma mutations, 131
- prognostic value of mutations, 126–127
- prospects for study, 131
- prostate cancer mutations, 131
- regulation
 - binding proteins, 129
 - 2-hydroxyglutarate, 128–129
 - vitamin C, 129–130
- structure and function, 127–128
- T-cell lymphoma mutations, 130–131

TMPRSS2, 204, 209

TOP2A, 97

TRAIL, 247–248

Transient abnormal myelopoiesis (TAM), 225

Tranlycypromine (TCP), 307–308, 311–312, 313

TRF1, 218

Trr, 69–71

Trx, 69

TWIST, 295

TWIST1, 27

U

UBC9, 203

UNC0638, 348

UNC0642, 348

Uterine cancer, ARID1A mutation, 92

UTX. *See* MLL3; MLL4

V

Vascular endothelial growth factor (VEGF), 250

VEGF. *See* Vascular endothelial growth factor

VEGFR1, 347

Vitamin C, TET2 regulation, 129–130

Vorinostat (SAHA), 254, 258

W

WDR5, 44

WEE1, 179

WHISTLE, 28

WHS. *See* Wolf–Hirschorn syndrome

WNT, 206

Wolf–Hirschorn syndrome (WHS), 25, 27

WT1, 129

X

Xist, 363

Y

YK-4-272, 257

YY1, 363

Z

ZEB1, 249–250

ZEB2, 249